Skip to content

A characteristic study on the curative effect of Bushen Zhuyun Recipe in the treatment of recurrent abortion by pre-pregnancy intervention and regulation of endometrial receptivity

A randomized controlled trial of Bushen Zhuyun Fang in the treatment of recurrent abortion by pre-pregnancy intervention and regulation of endometrial receptivity

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2022000031
Enrollment
Unknown
Registered
2022-06-22
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Habitual abortion

Interventions

therapy group:Bushen Zhuyun Fang+Western medicine placebo
control group:Femoston+Traditional Chinese medicine placebo

Sponsors

Xiyuan Hospital,
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for recurrent miscarriage. (2) Meet the diagnostic criteria for thin endometrium. (3) Those who are in line with TCM syndrome differentiation as kidney and spleen deficiency syndrome. (4) Aged 22-45 years old. (5) The regularity of the menstrual cycle. (6) Voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Does not meet the inclusion criteria (2) Three-dimensional B-ultrasound or hysteroscopy found intrauterine adhesions (3) Taking other drugs that affect endometrial thickness. (4) have uterine fibroids or reproductive tract malformations. (5) Abnormal autoimmune antibodies, chromosomal abnormalities and other factors. (6) Patients with other systemic heart, liver, kidney and other serious diseases.

Design outcomes

Primary

MeasureTime frame
Early pregnancy outcome;Endometrial thickness and type changes;

Secondary

MeasureTime frame
Estradiol;Endometrial blood flow changes;pregnancy rate;Chinese medicine symptom complex score;progesterone;vascular endothelial growth factor;Interleukin-8;

Countries

China

Contacts

Public ContactJINGHONG XIE

Xiyuan Hospital of CACMS

jinghongxie2012@163.com13522612006

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026